{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:14:38Z","timestamp":1793927678695,"version":"4.8.0"},"reference-count":194,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41581-019-0183-y","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T13:02:54Z","timestamp":1567688574000},"page":"735-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["The pathobiology of polycystic kidney disease from a metabolic viewpoint"],"prefix":"10.1038","volume":"15","author":[{"given":"Luis Fernando","family":"Menezes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-5588","authenticated-orcid":false,"given":"Gregory G.","family":"Germino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"183_CR1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"V Torres","year":"2007","unstructured":"Torres, V., Harris, P. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287\u20131301 (2007).","journal-title":"Lancet"},{"key":"183_CR2","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ki.2014.120","volume":"86","author":"EM Spithoven","year":"2014","unstructured":"Spithoven, E. M. et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 86, 1244\u20131252 (2014).","journal-title":"Kidney Int."},{"key":"183_CR3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ki.2015.95","volume":"88","author":"L Rodriguez-Osorio","year":"2015","unstructured":"Rodriguez-Osorio, L., Vanessa Perez-Gomez, M. & Ortiz, A. Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD. Kidney Int. 88, 194 (2015).","journal-title":"Kidney Int."},{"key":"183_CR4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier, R. W. et al. Blood pressure in early autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2255\u20132266 (2014).","journal-title":"N. Engl. J. Med."},{"key":"183_CR5","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","volume":"371","author":"VE Torres","year":"2014","unstructured":"Torres, V. E. et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N. Engl. J. Med. 371, 2267\u20132276 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"183_CR6","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"Vicente E. Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407-2418 (2012).","journal-title":"New England Journal of Medicine"},{"key":"183_CR7","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930\u20131942 (2017).","journal-title":"N. Engl. J. Med."},{"key":"183_CR8","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrneph.2017.127","volume":"13","author":"MB Lanktree","year":"2017","unstructured":"Lanktree, M. B. & Chapman, A. B. New treatment paradigms for ADPKD: moving towards precision medicine. Nat. Rev. Nephrol. 13, 750\u2013768 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"183_CR9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMra1700312","volume":"377","author":"K Kalantar-Zadeh","year":"2017","unstructured":"Kalantar-Zadeh, K. & Fouque, D. Nutritional management of chronic kidney disease. N. Engl. J. Med. 377, 1765\u20131776 (2017).","journal-title":"N. Engl. J. Med."},{"key":"183_CR10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","volume":"330","author":"S Klahr","year":"1994","unstructured":"Klahr, S. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N. Engl. J. Med. 330, 877\u2013884 (1994).","journal-title":"N. Engl. J. Med."},{"key":"183_CR11","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","volume":"5","author":"S Klahr","year":"1995","unstructured":"Klahr, S. et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J. Am. Soc. Nephrol. 5, 2037\u20132047 (1995).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR12","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","volume":"27","author":"G Warner","year":"2016","unstructured":"Warner, G. et al. Food restriction ameliorates the development of polycystic kidney disease. J. Am. Soc. Nephrol. 27, 1437\u20131447 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","volume":"14","author":"V Padovano","year":"2018","unstructured":"Padovano, V., Podrini, C., Boletta, A. & Caplan, M. J. Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat. Rev. Nephrol. 14, 678\u2013687 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"183_CR14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1042\/bj20031061","volume":"375","author":"DM Cooper","year":"2003","unstructured":"Cooper, D. M. Regulation and organization of adenylyl cyclases and cAMP. Biochem. J. 375, 517\u2013529 (2003).","journal-title":"Biochem. J."},{"key":"183_CR15","doi-asserted-by":"crossref","first-page":"F1412","DOI":"10.1152\/ajprenal.00692.2011","volume":"303","author":"CS Pinto","year":"2012","unstructured":"Pinto, C. S., Reif, G. A., Nivens, E., White, C. & Wallace, D. P. Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl\u2212 secretion by human autosomal dominant polycystic kidney cells. Am. J. Physiol. Ren. Physiol. 303, F1412\u2013F1424 (2012).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"183_CR16","doi-asserted-by":"crossref","first-page":"15922","DOI":"10.1074\/jbc.M212475200","volume":"278","author":"TN Litvin","year":"2003","unstructured":"Litvin, T. N., Kamenetsky, M., Zarifyan, A., Buck, J. & Levin, L. R. Kinetic properties of \"soluble\" adenylyl cyclase. Synergism between calcium and bicarbonate. J. Biol. Chem. 278, 15922\u201315926 (2003).","journal-title":"J. Biol. Chem."},{"issue":"12","key":"183_CR17","doi-asserted-by":"publisher","first-page":"a011148","DOI":"10.1101\/cshperspect.a011148","volume":"4","author":"P. Sassone-Corsi","year":"2012","unstructured":"Sassone-Corsi, P. The cyclic AMP pathway. Cold Spring Harb. Perspect. Biol. https:\/\/doi.org\/10.1101\/cshperspect.a011148 (2012).","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"183_CR18","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.cellsig.2010.05.014","volume":"22","author":"M Metrich","year":"2010","unstructured":"Metrich, M. et al. Epac activation induces histone deacetylase nuclear export via a Ras-dependent signalling pathway. Cell Signal. 22, 1459\u20131468 (2010).","journal-title":"Cell Signal."},{"key":"183_CR19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1152\/physrev.00008.2002","volume":"82","author":"UB Kaupp","year":"2002","unstructured":"Kaupp, U. B. & Seifert, R. Cyclic nucleotide-gated ion channels. Physiol. Rev. 82, 769\u2013824 (2002).","journal-title":"Physiol. Rev."},{"key":"183_CR20","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1096\/fasebj.3.14.2480260","volume":"3","author":"R Mangoo-Karim","year":"1989","unstructured":"Mangoo-Karim, R. et al. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB J. 3, 2629\u20132632 (1989).","journal-title":"FASEB J."},{"key":"183_CR21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","volume":"30","author":"T Yamaguchi","year":"1997","unstructured":"Yamaguchi, T., Nagao, S., Kasahara, M., Takahashi, H. & Grantham, J. J. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am. J. Kidney Dis. 30, 703\u2013709 (1997).","journal-title":"Am. J. Kidney Dis."},{"key":"183_CR22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ki.1996.304","volume":"50","author":"CJ Davidow","year":"1996","unstructured":"Davidow, C. J., Maser, R. L., Rome, L. A., Calvet, J. P. & Grantham, J. J. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int. 50, 208\u2013218 (1996).","journal-title":"Kidney Int."},{"key":"183_CR23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","volume":"11","author":"K Hanaoka","year":"2000","unstructured":"Hanaoka, K. & Guggino, W. B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 11, 1179\u20131187 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bbadis.2010.11.005","volume":"1812","author":"DP Wallace","year":"2011","unstructured":"Wallace, D. P. Cyclic AMP-mediated cyst expansion. Biochim. Biophys. Acta 1812, 1291\u20131300 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"183_CR25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1053\/ajkd.2001.28614","volume":"38","author":"GA Tanner","year":"2001","unstructured":"Tanner, G. A. & Tanner, J. A. Chronic caffeine consumption exacerbates hypertension in rats with polycystic kidney disease. Am. J. Kidney Dis. 38, 1089\u20131095 (2001).","journal-title":"Am. J. Kidney Dis."},{"key":"183_CR26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone","year":"2003","unstructured":"Gattone, V. H., Wang, X., Harris, P. C. & Torres, V. E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323\u20131326 (2003).","journal-title":"Nat. Med."},{"key":"183_CR27","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","volume":"26","author":"E Meijer","year":"2011","unstructured":"Meijer, E. et al. Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol. Dial. Transpl. 26, 2445\u20132453 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"183_CR28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp, K. et al. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J. Am. Soc. Nephrol. 26, 39\u201347 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"V Torres","year":"2004","unstructured":"Torres, V. et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 10, 363\u2013364 (2004).","journal-title":"Nat. Med."},{"key":"183_CR30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang, X., Wu, Y., Ward, C. J., Harris, P. C. & Torres, V. E. Vasopressin directly regulates cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 19, 102\u2013108 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.2013010077","volume":"25","author":"S Rees","year":"2014","unstructured":"Rees, S. et al. Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J. Am. Soc. Nephrol. 25, 232\u2013237 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR32","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1681\/ASN.2015010057","volume":"27","author":"H Ye","year":"2016","unstructured":"Ye, H. et al. Modulation of polycystic kidney disease severity by phosphodiesterase 1 and 3 subfamilies. J. Am. Soc. Nephrol. 27, 1312\u20131320 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000448693","volume":"44","author":"D Zittema","year":"2016","unstructured":"Zittema, D. et al. Dose-titrated vasopressin V2 receptor antagonist improves renoprotection in a mouse model for autosomal dominant polycystic kidney disease. Am. J. Nephrol. 44, 194\u2013203 (2016).","journal-title":"Am. J. Nephrol."},{"key":"183_CR34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/1471-2369-14-233","volume":"14","author":"J Roix","year":"2013","unstructured":"Roix, J. & Saha, S. TNF-\u03b1 blockade is ineffective in animal models of established polycystic kidney disease. BMC Nephrol. 14, 233 (2013).","journal-title":"BMC Nephrol."},{"key":"183_CR35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres, V. E. et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol. Dial. Transpl. 33, 477\u2013489 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"183_CR36","unstructured":"FDA. Risk Evaluation Mitigation Strategy (REMS) Document. JYNARQUE (tolvaptan) REMS program. FDA https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/204441Orig1s000REMS.pdf (2018)."},{"key":"183_CR37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","volume":"13","author":"ME Edwards","year":"2018","unstructured":"Edwards, M. E. et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 13, 1153\u20131161 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"183_CR38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti, P. et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 68, 206\u2013216 (2005).","journal-title":"Kidney Int."},{"key":"183_CR39","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli, A. et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382, 1485\u20131495 (2013).","journal-title":"Lancet"},{"key":"183_CR40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002777","volume":"16","author":"N Perico","year":"2019","unstructured":"Perico, N. et al. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial. PLOS Med. 16, e1002777 (2019).","journal-title":"PLOS Med."},{"key":"183_CR41","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","volume":"320","author":"E Meijer","year":"2018","unstructured":"Meijer, E. et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA 320, 2010\u20132019 (2018).","journal-title":"JAMA"},{"key":"183_CR42","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","volume":"17","author":"S Nagao","year":"2006","unstructured":"Nagao, S. et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J. Am. Soc. Nephrol. 17, 2220\u20132227 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR43","doi-asserted-by":"crossref","first-page":"F261","DOI":"10.1152\/ajprenal.00345.2014","volume":"308","author":"K Hopp","year":"2015","unstructured":"Hopp, K. et al. Effects of hydration in rats and mice with polycystic kidney disease. Am. J. Physiol. Renal Physiol. 308, F261\u2013F266 (2015).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"183_CR44","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","volume":"29","author":"E Higashihara","year":"2014","unstructured":"Higashihara, E. et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol. Dial. Transpl. 29, 1710\u20131719 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"183_CR45","volume":"8","author":"ATY Wong","year":"2018","unstructured":"Wong, A. T. Y. et al. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8, e018794 (2018).","journal-title":"BMJ Open"},{"key":"183_CR46","volume":"8","author":"R El-Damanawi","year":"2018","unstructured":"El-Damanawi, R. et al. Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial. BMJ Open 8, e022859 (2018).","journal-title":"BMJ Open"},{"key":"183_CR47","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1097\/01.ASN.0000025282.48298.7B","volume":"13","author":"FA Belibi","year":"2002","unstructured":"Belibi, F. A. et al. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 13, 2723\u20132729 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1590\/S0100-879X2012007500120","volume":"45","author":"LC Vendramini","year":"2012","unstructured":"Vendramini, L. C., Nishiura, J. L., Baxmann, A. C. & Heilberg, I. P. Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz. J. Med. Biol. Res. 45, 834\u2013840 (2012).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"183_CR49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40620-017-0396-8","volume":"31","author":"L Girardat-Rotar","year":"2017","unstructured":"Girardat-Rotar, L., Puhan, M. A., Braun, J. & Serra, A. L. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a prospective longitudinal cohort study. J. Nephrol. 31, 87\u201394 (2017).","journal-title":"J. Nephrol."},{"key":"183_CR50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1123\/ijsnem.15.3.252","volume":"15","author":"LE Armstrong","year":"2005","unstructured":"Armstrong, L. E. et al. Fluid, electrolyte, and renal indices of hydration during 11 days of controlled caffeine consumption. Int. J. Sport Nutr. Exerc. Metab. 15, 252\u2013265 (2005).","journal-title":"Int. J. Sport Nutr. Exerc. Metab."},{"key":"183_CR51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/509282a","volume":"509","author":"JA Clayton","year":"2014","unstructured":"Clayton, J. A. & Collins, F. S. Policy: NIH to balance sex in cell and animal studies. Nature 509, 282\u2013283 (2014).","journal-title":"Nature"},{"key":"183_CR52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1096\/fj.15-279554","volume":"30","author":"JA Clayton","year":"2016","unstructured":"Clayton, J. A. Studying both sexes: a guiding principle for biomedicine. FASEB J. 30, 519\u2013524 (2016).","journal-title":"FASEB J."},{"key":"183_CR53","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jama.298.8.880","volume":"298","author":"NA Patsopoulos","year":"2007","unstructured":"Patsopoulos, N. A., Tatsioni, A. & Ioannidis, J. P. Claims of sex differences: an empirical assessment in genetic associations. JAMA 298, 880\u2013893 (2007).","journal-title":"JAMA"},{"key":"183_CR54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nrg2415","volume":"9","author":"C Ober","year":"2008","unstructured":"Ober, C., Loisel, D. A. & Gilad, Y. Sex-specific genetic architecture of human disease. Nat. Rev. Genet. 9, 911\u2013922 (2008).","journal-title":"Nat. Rev. Genet."},{"key":"183_CR55","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00199.2010","volume":"300","author":"J Liu","year":"2011","unstructured":"Liu, J. et al. Sex differences in vasopressin V2 receptor expression and vasopressin-induced antidiuresis. Am. J. Physiol. Ren. Physiol. 300, F433\u2013F440 (2011).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"183_CR56","doi-asserted-by":"crossref","first-page":"F124","DOI":"10.1152\/ajprenal.00029.2004","volume":"287","author":"M Ljubojevic","year":"2004","unstructured":"Ljubojevic, M. et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am. J. Physiol. Renal Physiol. 287, F124\u2013F138 (2004).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"183_CR57","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1681\/ASN.2017030295","volume":"28","author":"LC Veiras","year":"2017","unstructured":"Veiras, L. C. et al. Sexual dimorphic pattern of renal transporters and electrolyte homeostasis. J. Am. Soc. Nephrol. 28, 3504\u20133517 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ebiom.2016.01.027","volume":"5","author":"LF Menezes","year":"2016","unstructured":"Menezes, L. F., Lin, C. C., Zhou, F. & Germino, G. G. Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. EBioMedicine 5, 183\u2013192 (2016).","journal-title":"EBioMedicine"},{"key":"183_CR59","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1523-1755.2002.kid590.x","volume":"62","author":"V M\u00fcller","year":"2002","unstructured":"M\u00fcller, V. et al. Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int. 62, 1364\u20131371 (2002).","journal-title":"Kidney Int."},{"key":"183_CR60","doi-asserted-by":"crossref","first-page":"52282","DOI":"10.1074\/jbc.M407629200","volume":"279","author":"KM Park","year":"2004","unstructured":"Park, K. M., Kim, J. I., Ahn, Y., Bonventre, A. J. & Bonventre, J. V. Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J. Biol. Chem. 279, 52282\u201352292 (2004).","journal-title":"J. Biol. Chem."},{"key":"183_CR61","doi-asserted-by":"crossref","first-page":"R951","DOI":"10.1152\/ajpregu.00360.2012","volume":"304","author":"A Soljancic","year":"2013","unstructured":"Soljancic, A. et al. Protective role of testosterone in ischemia-reperfusion-induced acute kidney injury. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304, R951\u2013R958 (2013).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"183_CR62","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ejphar.2013.07.008","volume":"714","author":"R Tanaka","year":"2013","unstructured":"Tanaka, R. et al. Sex differences in ischemia\/reperfusion-induced acute kidney injury are dependent on the renal sympathetic nervous system. Eur. J. Pharmacol. 714, 397\u2013404 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"183_CR63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.ackd.2013.05.004","volume":"20","author":"J Neugarten","year":"2013","unstructured":"Neugarten, J. & Golestaneh, L. Gender and the prevalence and progression of renal disease. Adv. Chronic Kidney Dis. 20, 390\u2013395 (2013).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"183_CR64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1681\/ASN.V112319","volume":"11","author":"J Neugarten","year":"2000","unstructured":"Neugarten, J., Acharya, A. & Silbiger, S. R. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J. Am. Soc. Nephrol. 11, 319\u2013329 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR65","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0092-8674(00)81793-6","volume":"87","author":"F Qian","year":"1996","unstructured":"Qian, F., Watnick, T. J., Onuchic, L. F. & Germino, G. G. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87, 979\u2013987 (1996).","journal-title":"Cell"},{"key":"183_CR66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ajkd.2007.10.037","volume":"51","author":"BY Reed","year":"2008","unstructured":"Reed, B. Y. et al. Variation in age at ESRD in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 51, 173\u2013183 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"183_CR67","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/01.ASN.0000061774.90975.25","volume":"14","author":"R Magistroni","year":"2003","unstructured":"Magistroni, R. et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 14, 1164\u20131174 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR68","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ki.1995.319","volume":"48","author":"N Gretz","year":"1995","unstructured":"Gretz, N. et al. Gender-dependent disease severity in autosomal polycystic kidney disease of rats. Kidney Int. 48, 496\u2013500 (1995).","journal-title":"Kidney Int."},{"key":"183_CR69","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0272-6386(96)90525-9","volume":"27","author":"BD Cowley","year":"1996","unstructured":"Cowley, B. D., Grantham, J. J., Muessel, M. J., Kraybill, A. L. & Gattone, V. H. Modification of disease progression in rats with inherited polycystic kidney disease. Am. J. Kidney Dis. 27, 865\u2013879 (1996).","journal-title":"Am. J. Kidney Dis."},{"key":"183_CR70","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1681\/ASN.2004070595","volume":"16","author":"S Nagao","year":"2005","unstructured":"Nagao, S. et al. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 16, 2052\u20132062 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR71","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1523-1755.2005.00589.x","volume":"68","author":"KD Stringer","year":"2005","unstructured":"Stringer, K. D. et al. Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int. 68, 1729\u20131739 (2005).","journal-title":"Kidney Int."},{"key":"183_CR72","doi-asserted-by":"crossref","first-page":"F636","DOI":"10.1152\/ajprenal.00265.2011","volume":"302","author":"S Anderson","year":"2012","unstructured":"Anderson, S. et al. 2-Hydroxyestradiol slows progression of experimental polycystic kidney disease. Am. J. Physiol. Renal Physiol. 302, F636\u2013F645 (2012).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"183_CR73","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1523-1755.2001.00473.x","volume":"59","author":"DJ Lager","year":"2001","unstructured":"Lager, D. J., Qian, Q., Bengal, R. J., Ishibashi, M. & Torres, V. E. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int. 59, 126\u2013136 (2001).","journal-title":"Kidney Int."},{"key":"183_CR74","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","volume":"17","author":"LA Smith","year":"2006","unstructured":"Smith, L. A. et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J. Am. Soc. Nephrol. 17, 2821\u20132831 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR75","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.cmet.2017.04.033","volume":"25","author":"F Mauvais-Jarvis","year":"2017","unstructured":"Mauvais-Jarvis, F., Arnold, A. P. & Reue, K. A guide for the design of pre-clinical studies on sex differences in metabolism. Cell Metab. 25, 1216\u20131230 (2017).","journal-title":"Cell Metab."},{"key":"183_CR76","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.celrep.2014.07.013","volume":"8","author":"D Ronen","year":"2014","unstructured":"Ronen, D. & Benvenisty, N. Sex-dependent gene expression in human pluripotent stem cells. Cell Rep. 8, 923\u2013932 (2014).","journal-title":"Cell Rep."},{"key":"183_CR77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37\u201346 (2015).","journal-title":"Nat. Med."},{"key":"183_CR78","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm1675","volume":"13","author":"K Piontek","year":"2007","unstructured":"Piontek, K., Menezes, L., Garcia-Gonzalez, M., Huso, D. & Germino, G. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat. Med. 13, 1490\u20131495 (2007).","journal-title":"Nat. Med."},{"key":"183_CR79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003053","volume":"8","author":"LF Menezes","year":"2012","unstructured":"Menezes, L. F. et al. Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4\u03b1 as a disease modifier. PLoS Genet. 8, e1003053 (2012).","journal-title":"PLoS Genet."},{"key":"183_CR80","doi-asserted-by":"crossref","first-page":"37991","DOI":"10.1074\/jbc.M205087200","volume":"277","author":"JF Louet","year":"2002","unstructured":"Louet, J. F., Hayhurst, G., Gonzalez, F. J., Girard, J. & Decaux, J. F. The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB). J. Biol. Chem. 277, 37991\u201338000 (2002).","journal-title":"J. Biol. Chem."},{"key":"183_CR81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/hmg\/ddi421","volume":"15","author":"E Allen","year":"2006","unstructured":"Allen, E. et al. Loss of polycystin-1 or polycystin-2 results in dysregulated apolipoprotein expression in murine tissues via alterations in nuclear hormone receptors. Hum. Mol. Genet. 15, 11\u201321 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"183_CR82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012821","volume":"5","author":"MA Garcia-Gonzalez","year":"2010","unstructured":"Garcia-Gonzalez, M. A. et al. Pkd1 and Pkd2 are required for normal placental development. PLOS ONE 5, e12821 (2010).","journal-title":"PLOS ONE"},{"key":"183_CR83","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe, I. et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488\u2013493 (2013).","journal-title":"Nat. Med."},{"key":"183_CR84","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1681\/ASN.2015030231","volume":"27","author":"M Chiaravalli","year":"2016","unstructured":"Chiaravalli, M. et al. 2-Deoxy-d-glucose ameliorates PKD progression. J. Am. Soc. Nephrol. 27, 1958\u20131969 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR85","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.celrep.2016.07.036","volume":"16","author":"S Izreig","year":"2016","unstructured":"Izreig, S. et al. The miR-17 approximately 92 microRNA cluster is a global regulator of tumor metabolism. Cell Rep. 16, 1915\u20131928 (2016).","journal-title":"Cell Rep."},{"key":"183_CR86","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14395","volume":"8","author":"S Hajarnis","year":"2017","unstructured":"Hajarnis, S. et al. microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat. Commun. 8, 14395 (2017).","journal-title":"Nat. Commun"},{"key":"183_CR87","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne, N. et al. Molecular actions of PPARalpha in lipid metabolism and inflammation. Endocr. Rev. 39, 760\u2013802 (2018).","journal-title":"Endocr. Rev."},{"key":"183_CR88","doi-asserted-by":"crossref","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","volume":"314","author":"R Lakhia","year":"2018","unstructured":"Lakhia, R. et al. PPARalpha agonist fenofibrate enhances fatty acid \u03b2-oxidation and attenuates polycystic kidney and liver disease in mice. Am. J. Physiol. Renal Physiol. 314, F122\u2013F131 (2018).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"183_CR89","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/bj1120149","volume":"112","author":"MJ Weidemann","year":"1969","unstructured":"Weidemann, M. J. & Krebs, H. A. The fuel of respiration of rat kidney cortex. Biochem. J. 112, 149\u2013166 (1969).","journal-title":"Biochem. J."},{"key":"183_CR90","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature17184","volume":"531","author":"MT Tran","year":"2016","unstructured":"Tran, M. T. et al. PGC1\u03b1 drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531, 528\u2013532 (2016).","journal-title":"Nature"},{"key":"183_CR91","volume":"8","author":"CC Lin","year":"2018","unstructured":"Lin, C. C. et al. A cleavage product of polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci. Rep. 8, 2743 (2018).","journal-title":"Sci. Rep."},{"key":"183_CR92","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.celrep.2014.03.064","volume":"7","author":"P Outeda","year":"2014","unstructured":"Outeda, P. et al. Polycystin signaling is required for directed endothelial cell migration and lymphatic development. Cell Rep. 7, 634\u2013644 (2014).","journal-title":"Cell Rep."},{"key":"183_CR93","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature14362","volume":"520","author":"S Schoors","year":"2015","unstructured":"Schoors, S. et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520, 192\u2013197 (2015).","journal-title":"Nature"},{"key":"183_CR94","volume":"9","author":"EM Flowers","year":"2018","unstructured":"Flowers, E. M. et al. Lkb1 deficiency confers glutamine dependency in polycystic kidney disease. Nat. Commun. 9, 814 (2018).","journal-title":"Nat. Commun"},{"key":"183_CR95","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s42003-018-0200-x","volume":"1","author":"C Podrini","year":"2018","unstructured":"Podrini, C. et al. Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways. Commun. Biol. 1, 194 (2018).","journal-title":"Commun. Biol."},{"key":"183_CR96","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.molcel.2014.08.018","volume":"56","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol. Cell 56, 205\u2013218 (2014).","journal-title":"Mol. Cell"},{"key":"183_CR97","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/ndt\/gfx349","volume":"33","author":"I Soomro","year":"2018","unstructured":"Soomro, I. et al. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. Nephrol. Dial. Transpl. 33, 1343\u20131353 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"183_CR98","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","volume":"20","author":"J Adam","year":"2011","unstructured":"Adam, J. et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif\/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524\u2013537 (2011).","journal-title":"Cancer Cell"},{"key":"183_CR99","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajmg.1320320326","volume":"32","author":"GN Wilson","year":"1989","unstructured":"Wilson, G. N. et al. Glutaric aciduria type II: review of the phenotype and report of an unusual glomerulopathy. Am. J. Med. Genet. 32, 395\u2013401 (1989).","journal-title":"Am. J. Med. Genet."},{"key":"183_CR100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0022-3476(86)80429-2","volume":"109","author":"GN Wilson","year":"1986","unstructured":"Wilson, G. N. What is Zellweger syndrome? J. Pediatr. 109, 398 (1986).","journal-title":"J. Pediatr."},{"key":"183_CR101","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrneph.2015.46","volume":"11","author":"T Seeger-Nukpezah","year":"2015","unstructured":"Seeger-Nukpezah, T., Geynisman, D. M., Nikonova, A. S., Benzing, T. & Golemis, E. A. The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat. Rev. Nephrol. 11, 515\u2013534 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"183_CR102","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo, A., Gui, D. Y. & Vander Heiden, M. G. Targeting metabolism for cancer therapy. Cell Chem. Biol. 24, 1161\u20131180 (2017).","journal-title":"Cell Chem. Biol."},{"key":"183_CR103","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V. & Locasale, J. W. The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211\u2013218 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"183_CR104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cmet.2018.07.020","volume":"28","author":"KD Courtney","year":"2018","unstructured":"Courtney, K. D. et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo. Cell Metab. 28, 793\u2013800 e792 (2018).","journal-title":"Cell Metab."},{"key":"183_CR105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/13543784.2015.960077","volume":"24","author":"DW Sborov","year":"2015","unstructured":"Sborov, D. W., Haverkos, B. M. & Harris, P. J. Investigational cancer drugs targeting cell metabolism in clinical development. Expert. Opin. Investig. Drugs 24, 79\u201394 (2015).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"183_CR106","unstructured":"Pascual, G., Dominguez, D. & Benitah, S. A. The contributions of cancer cell metabolism to metastasis. Dis. Model. Mech. 11, dmm032920 (2018)."},{"key":"183_CR107","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ceb.2014.12.001","volume":"33","author":"V Albert","year":"2015","unstructured":"Albert, V. & Hall, M. N. mTOR signaling in cellular and organismal energetics. Curr. Opin. Cell Biol. 33, 55\u201366 (2015).","journal-title":"Curr. Opin. Cell Biol."},{"key":"183_CR108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2016.108","volume":"12","author":"D Fantus","year":"2016","unstructured":"Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B. & Thomson, A. W. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat. Rev. Nephrol. 12, 587\u2013609 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"183_CR109","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske, E. P., Jozwiak, S., Kingswood, J. C., Sampson, J. R. & Thiele, E. A. Tuberous sclerosis complex. Nat. Rev. Dis. Prim. 2, 16035 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"183_CR110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1294-328","volume":"8","author":"PT Brook-Carter","year":"1994","unstructured":"Brook-Carter, P. T. et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease \u2013 a contiguous gene syndrome. Nat. Genet. 8, 328\u2013332 (1994).","journal-title":"Nat. Genet."},{"key":"183_CR111","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"J Shillingford","year":"2006","unstructured":"Shillingford, J. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. USA 103, 5466\u20135471 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"183_CR112","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","volume":"21","author":"J Shillingford","year":"2010","unstructured":"Shillingford, J., Piontek, K., Germino, G. & Weimbs, T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 21, 489\u2013497 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR113","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10786","volume":"7","author":"M Pema","year":"2016","unstructured":"Pema, M. et al. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat. Commun. 7, 10786 (2016).","journal-title":"Nat. Commun."},{"key":"183_CR114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","volume":"485","author":"AC Hsieh","year":"2012","unstructured":"Hsieh, A. C. et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55\u201361 (2012).","journal-title":"Nature"},{"key":"183_CR115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature11083","volume":"485","author":"CC Thoreen","year":"2012","unstructured":"Thoreen, C. C. et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109\u2013113 (2012).","journal-title":"Nature"},{"key":"183_CR116","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.cmet.2013.10.001","volume":"18","author":"M Morita","year":"2013","unstructured":"Morita, M. et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 18, 698\u2013711 (2013).","journal-title":"Cell Metab."},{"key":"183_CR117","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","volume":"39","author":"K Duvel","year":"2010","unstructured":"Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171\u2013183 (2010).","journal-title":"Mol. Cell"},{"key":"183_CR118","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","volume":"284","author":"CC Thoreen","year":"2009","unstructured":"Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023\u20138032 (2009).","journal-title":"J. Biol. Chem."},{"key":"183_CR119","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1073\/pnas.1201689109","volume":"109","author":"O Larsson","year":"2012","unstructured":"Larsson, O. et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl. Acad. Sci. USA 109, 8977\u20138982 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"183_CR120","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1074\/jbc.M210621200","volume":"278","author":"KR Hallows","year":"2003","unstructured":"Hallows, K. R., McCane, J. E., Kemp, B. E., Witters, L. A. & Foskett, J. K. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. J. Biol. Chem. 278, 998\u20131004 (2003).","journal-title":"J. Biol. Chem."},{"key":"183_CR121","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar, V. et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl. Acad. Sci. USA 108, 2462\u20132467 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"183_CR122","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","volume":"47","author":"SL Seliger","year":"2018","unstructured":"Seliger, S. L. et al. A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. Am. J. Nephrol. 47, 352\u2013360 (2018).","journal-title":"Am. J. Nephrol."},{"key":"183_CR123","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820\u2013829 (2010).","journal-title":"N. Engl. J. Med."},{"key":"183_CR124","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830\u2013840 (2010).","journal-title":"N. Engl. J. Med."},{"key":"183_CR125","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","volume":"10","author":"G Canaud","year":"2010","unstructured":"Canaud, G. et al. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Am. J. Transpl. 10, 1701\u20131706 (2010).","journal-title":"Am. J. Transpl."},{"key":"183_CR126","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrneph.2014.192","volume":"10","author":"N Jain","year":"2014","unstructured":"Jain, N. & Reilly, R. F. Effects of dietary interventions on incidence and progression of CKD. Nat. Rev. Nephrol. 10, 712\u2013724 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"183_CR127","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1681\/ASN.V561355","volume":"5","author":"K Tomobe","year":"1994","unstructured":"Tomobe, K. et al. Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J. Am. Soc. Nephrol. 5, 1355\u20131360 (1994).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR128","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1681\/ASN.V661649","volume":"6","author":"MR Ogborn","year":"1995","unstructured":"Ogborn, M. R. & Sareen, S. Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat. J. Am. Soc. Nephrol. 6, 1649\u20131654 (1995).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR129","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1172\/JCI74915","volume":"124","author":"T Laeger","year":"2014","unstructured":"Laeger, T. et al. FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 124, 3913\u20133922 (2014).","journal-title":"J. Clin. Invest."},{"key":"183_CR130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1681\/ASN.V102300","volume":"10","author":"HM Aukema","year":"1999","unstructured":"Aukema, H. M., Housini, I. & Rawling, J. M. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J. Am. Soc. Nephrol. 10, 300\u2013308 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR131","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1523-1755.2000.00835.x","volume":"57","author":"MR Ogborn","year":"2000","unstructured":"Ogborn, M. R., Nitschmann, E., Weiler, H. A. & Bankovic-Calic, N. Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int. 57, 159\u2013166 (2000).","journal-title":"Kidney Int."},{"key":"183_CR132","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1523-1755.2001.00465.x","volume":"59","author":"HM Aukema","year":"2001","unstructured":"Aukema, H. M. & Housini, I. Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int. 59, 52\u201361 (2001).","journal-title":"Kidney Int."},{"key":"183_CR133","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jn\/130.9.2356","volume":"130","author":"S Jayapalan","year":"2000","unstructured":"Jayapalan, S., Saboorian, M. H., Edmunds, J. W. & Aukema, H. M. High dietary fat intake increases renal cyst disease progression in Han:SPRD-cy rats. J. Nutr. 130, 2356\u20132360 (2000).","journal-title":"J. Nutr."},{"key":"183_CR134","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature11432","volume":"489","author":"JA Mattison","year":"2012","unstructured":"Mattison, J. A. et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489, 318\u2013321 (2012).","journal-title":"Nature"},{"key":"183_CR135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1126\/science.1173635","volume":"325","author":"RJ Colman","year":"2009","unstructured":"Colman, R. J. et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325, 201\u2013204 (2009).","journal-title":"Science"},{"key":"183_CR136","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2016.1189","volume":"176","author":"CK Martin","year":"2016","unstructured":"Martin, C. K. et al. Effect of calorie restriction on mood, quality of life, sleep, and sexual function in healthy nonobese adults: the CALERIE 2 randomized clinical trial. JAMA Intern. Med. 176, 743\u2013752 (2016).","journal-title":"JAMA Intern. Med."},{"key":"183_CR137","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4093\/dmj.2014.38.5.321","volume":"38","author":"Y Wang","year":"2014","unstructured":"Wang, Y. Molecular links between caloric restriction and Sir2\/SIRT1 activation. Diabetes Metab. J. 38, 321\u2013329 (2014).","journal-title":"Diabetes Metab. J."},{"key":"183_CR138","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1172\/JCI64401","volume":"123","author":"X Zhou","year":"2013","unstructured":"Zhou, X. et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J. Clin. Invest. 123, 3084\u20133098 (2013).","journal-title":"J. Clin. Invest."},{"key":"183_CR139","unstructured":"US Department of Health and Human Services. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03342742 (2018)."},{"key":"183_CR140","doi-asserted-by":"publisher","unstructured":"Ishimoto, Y. et al. Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol. Cell Biol. https:\/\/doi.org\/10.1128\/MCB.00337-17 (2017).","DOI":"10.1128\/MCB.00337-17"},{"key":"183_CR141","volume":"12","author":"IY Kuo","year":"2019","unstructured":"Kuo, I. Y. et al. Polycystin 2 regulates mitochondrial Ca2+ signaling, bioenergetics, and dynamics through mitofusin 2. Sci. Signal. 12, eaat7397 (2019).","journal-title":"Sci. Signal."},{"key":"183_CR142","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1091\/mbc.e16-08-0597","volume":"28","author":"V Padovano","year":"2017","unstructured":"Padovano, V. et al. The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function. Mol. Biol. Cell 28, 261\u2013269 (2017).","journal-title":"Mol. Biol. Cell"},{"key":"183_CR143","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.bbabio.2015.06.016","volume":"1847","author":"AV Zhdanov","year":"2015","unstructured":"Zhdanov, A. V., Okkelman, I. A., Collins, F. W., Melgar, S. & Papkovsky, D. B. A novel effect of DMOG on cell metabolism: direct inhibition of mitochondrial function precedes HIF target gene expression. Biochim. Biophys. Acta 1847, 1254\u20131266 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"183_CR144","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ng.860","volume":"43","author":"SV Fedeles","year":"2011","unstructured":"Fedeles, S. V. et al. A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation. Nat. Genet. 43, 639\u2013647 (2011).","journal-title":"Nat. Genet."},{"key":"183_CR145","volume":"12","author":"NS Chandel","year":"2014","unstructured":"Chandel, N. S. Mitochondria as signaling organelles. BMC Biol. 12, 34 (2014).","journal-title":"BMC Biol."},{"key":"183_CR146","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","volume":"324","author":"KE Wellen","year":"2009","unstructured":"Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076\u20131080 (2009).","journal-title":"Science"},{"key":"183_CR147","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmet.2014.06.004","volume":"20","author":"JV Lee","year":"2014","unstructured":"Lee, J. V. et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab. 20, 306\u2013319 (2014).","journal-title":"Cell Metab."},{"key":"183_CR148","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature21028","volume":"542","author":"BW Wong","year":"2017","unstructured":"Wong, B. W. et al. The role of fatty acid \u03b2-oxidation in lymphangiogenesis. Nature 542, 49\u201354 (2017).","journal-title":"Nature"},{"key":"183_CR149","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nature13312","volume":"511","author":"B Ghesquiere","year":"2014","unstructured":"Ghesquiere, B., Wong, B. W., Kuchnio, A. & Carmeliet, P. Metabolism of stromal and immune cells in health and disease. Nature 511, 167\u2013176 (2014).","journal-title":"Nature"},{"key":"183_CR150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature12985","volume":"505","author":"JR Friedman","year":"2014","unstructured":"Friedman, J. R. & Nunnari, J. Mitochondrial form and function. Nature 505, 335\u2013343 (2014).","journal-title":"Nature"},{"key":"183_CR151","doi-asserted-by":"crossref","DOI":"10.1038\/srep27114","volume":"6","author":"LL Gallegos","year":"2016","unstructured":"Gallegos, L. L. et al. A protein interaction map for cell-cell adhesion regulators identifies DUSP23 as a novel phosphatase for \u03b2-catenin. Sci. Rep. 6, 27114 (2016).","journal-title":"Sci. Rep."},{"key":"183_CR152","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2014.07.036","volume":"158","author":"A Sing","year":"2014","unstructured":"Sing, A. et al. The atypical cadherin fat directly regulates mitochondrial function and metabolic state. Cell 158, 1293\u20131308 (2014).","journal-title":"Cell"},{"key":"183_CR153","unstructured":"McDonough, A. A. & Thomson, S. C. in Brenner & Rector's The Kidney (eds Taal, M. W. et al.) (Elsevier Health Sciences, 2012)."},{"key":"183_CR154","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1152\/physrev.1986.66.2.469","volume":"66","author":"G Wirthensohn","year":"1986","unstructured":"Wirthensohn, G. & Guder, W. G. Renal substrate metabolism. Physiol. Rev. 66, 469\u2013497 (1986).","journal-title":"Physiol. Rev."},{"key":"183_CR155","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.aai8764","volume":"356","author":"Z Xu","year":"2017","unstructured":"Xu, Z. et al. Microtubules acquire resistance from mechanical breakage through intralumenal acetylation. Science 356, 328\u2013332 (2017).","journal-title":"Science"},{"key":"183_CR156","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/ng0803-355","volume":"34","author":"T Watnick","year":"2003","unstructured":"Watnick, T. & Germino, G. From cilia to cyst. Nat. Genet. 34, 355\u2013356 (2003).","journal-title":"Nat. Genet."},{"issue":"3","key":"183_CR157","doi-asserted-by":"publisher","first-page":"a028191","DOI":"10.1101\/cshperspect.a028191","volume":"9","author":"Daniela A. Braun","year":"2016","unstructured":"Braun, D. A. & Hildebrandt, F. Ciliopathies. Cold Spring Harb. Perspect. Biol. https:\/\/doi.org\/10.1101\/cshperspect.a028191 (2017).","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"183_CR158","doi-asserted-by":"crossref","first-page":"a028209","DOI":"10.1101\/cshperspect.a028209","volume":"9","author":"M Ma","year":"2017","unstructured":"Ma, M., Gallagher, A. R. & Somlo, S. Ciliary mechanisms of cyst formation in polycystic kidney disease. Cold Spring Harb. Perspect. Biol. 9, a028209 (2017).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"183_CR159","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1097\/01.ASN.0000029587.47950.25","volume":"13","author":"BK Yoder","year":"2002","unstructured":"Yoder, B. K., Hou, X. & Guay-Woodford, L. M. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J. Am. Soc. Nephrol. 13, 2508\u20132516 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR160","volume":"7,","author":"X Liu","year":"2018","unstructured":"Liu, X. et al. Polycystin-2 is an essential ion channel subunit in the primary cilium of the renal collecting duct epithelium. eLife 7, e33183 (2018).","journal-title":"eLife"},{"key":"183_CR161","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ng.2715","volume":"45","author":"M Ma","year":"2013","unstructured":"Ma, M., Tian, X., Igarashi, P., Pazour, G. J. & Somlo, S. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat. Genet. 45, 1004\u20131012 (2013).","journal-title":"Nat. Genet."},{"key":"183_CR162","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cub.2007.08.034","volume":"17","author":"JR Davenport","year":"2007","unstructured":"Davenport, J. R. et al. Disruption of intraflagellar transport in adult mice leads to obesity and slow-onset cystic kidney disease. Curr. Biol. 17, 1586\u20131594 (2007).","journal-title":"Curr. Biol."},{"key":"183_CR163","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2014.11.019","volume":"21","author":"EC Oh","year":"2015","unstructured":"Oh, E. C., Vasanth, S. & Katsanis, N. Metabolic regulation and energy homeostasis through the primary cilium. Cell Metab. 21, 21\u201331 (2015).","journal-title":"Cell Metab."},{"key":"183_CR164","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature12639","volume":"502","author":"O Pampliega","year":"2013","unstructured":"Pampliega, O. et al. Functional interaction between autophagy and ciliogenesis. Nature 502, 194\u2013200 (2013).","journal-title":"Nature"},{"key":"183_CR165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature12606","volume":"502","author":"Z Tang","year":"2013","unstructured":"Tang, Z. et al. Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar satellites. Nature 502, 254\u2013257 (2013).","journal-title":"Nature"},{"key":"183_CR166","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nature12693","volume":"502","author":"V Cianfanelli","year":"2013","unstructured":"Cianfanelli, V. & Cecconi, F. Cell biology: molecular clearance at the cell's antenna. Nature 502, 180\u2013181 (2013).","journal-title":"Nature"},{"key":"183_CR167","doi-asserted-by":"crossref","first-page":"F1235","DOI":"10.1152\/ajprenal.00348.2010","volume":"300","author":"F Belibi","year":"2011","unstructured":"Belibi, F. et al. Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) and autophagy in polycystic kidney disease (PKD). Am. J. Physiol. Renal Physiol. 300, F1235\u2013F1243 (2011).","journal-title":"Am. J. Physiol. RenalPhysiol."},{"key":"183_CR168","first-page":"158","volume":"26","author":"P Zhu","year":"2017","unstructured":"Zhu, P., Sieben, C. J., Xu, X., Harris, P. C. & Lin, X. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model. Hum. Mol. Genet. 26, 158\u2013172 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"183_CR169","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/ncb2117","volume":"12","author":"C Boehlke","year":"2010","unstructured":"Boehlke, C. et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat. Cell Biol. 12, 1115\u20131122 (2010).","journal-title":"Nat. Cell Biol."},{"key":"183_CR170","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201798615","volume":"37","author":"A Viau","year":"2018","unstructured":"Viau, A. et al. Cilia-localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney. EMBO J. 37, e98615 (2018).","journal-title":"EMBO J."},{"key":"183_CR171","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00232-001-0075-4","volume":"184","author":"HA Praetorius","year":"2001","unstructured":"Praetorius, H. A. & Spring, K. R. Bending the MDCK cell primary cilium increases intracellular calcium. J. Membr. Biol. 184, 71\u201379 (2001).","journal-title":"J. Membr. Biol."},{"key":"183_CR172","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1172\/JCI40076","volume":"120","author":"JF O'Toole","year":"2010","unstructured":"O'Toole, J. F. et al. Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy. J. Clin. Invest. 120, 791\u2013802 (2010).","journal-title":"J. Clin. Invest."},{"key":"183_CR173","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/ng.2681","volume":"45","author":"S Hoff","year":"2013","unstructured":"Hoff, S. et al. ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. Nat. Genet. 45, 951\u2013956 (2013).","journal-title":"Nat. Genet."},{"key":"183_CR174","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4161\/cc.23824","volume":"12","author":"S Majumder","year":"2013","unstructured":"Majumder, S. & Fisk, H. A. VDAC3 and Mps1 negatively regulate ciliogenesis. Cell Cycle 12, 849\u2013858 (2013).","journal-title":"Cell Cycle"},{"key":"183_CR175","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1124\/jpet.112.192153","volume":"342","author":"EN Maldonado","year":"2012","unstructured":"Maldonado, E. N. & Lemasters, J. J. Warburg revisited: regulation of mitochondrial metabolism by voltage-dependent anion channels in cancer cells. J. Pharmacol. Exp. Ther. 342, 637\u2013641 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Pt A","key":"183_CR176","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mito.2014.07.009","volume":"19","author":"C Martel","year":"2014","unstructured":"Martel, C., Wang, Z. & Brenner, C. VDAC phosphorylation, a lipid sensor influencing the cell fate. Mitochondrion 19 (Pt A), 69\u201377 (2014).","journal-title":"Mitochondrion"},{"key":"183_CR177","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-physiol-022516-034219","volume":"79","author":"SC Huen","year":"2017","unstructured":"Huen, S. C. & Cantley, L. G. Macrophages in renal injury and repair. Annu. Rev. Physiol. 79, 449\u2013469 (2017).","journal-title":"Annu. Rev. Physiol."},{"key":"183_CR178","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2009060615","volume":"22","author":"S Lee","year":"2011","unstructured":"Lee, S. et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 22, 317\u2013326 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR179","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","volume":"22","author":"A Karihaloo","year":"2011","unstructured":"Karihaloo, A. et al. Macrophages promote cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 22, 1809\u20131814 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR180","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.2012.446","volume":"83","author":"KI Swenson-Fields","year":"2013","unstructured":"Swenson-Fields, K. I. et al. Macrophages promote polycystic kidney disease progression. Kidney Int. 83, 855\u2013864 (2013).","journal-title":"Kidney Int."},{"key":"183_CR181","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1681\/ASN.2018050518","volume":"29","author":"MF Cassini","year":"2018","unstructured":"Cassini, M. F. et al. Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 29, 2471\u20132481 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR182","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm.2627","volume":"18","author":"O Osborn","year":"2012","unstructured":"Osborn, O. & Olefsky, J. M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18, 363\u2013374 (2012).","journal-title":"Nat. Med."},{"key":"183_CR183","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.4049\/jimmunol.1402469","volume":"194","author":"Z Tan","year":"2015","unstructured":"Tan, Z. et al. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J. Immunol. 194, 6082\u20136089 (2015).","journal-title":"J. Immunol."},{"key":"183_CR184","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1172\/JCI120845","volume":"128","author":"MN Sack","year":"2018","unstructured":"Sack, M. N. Mitochondrial fidelity and metabolic agility control immune cell fate and function. J. Clin. Invest. 128, 3651\u20133661 (2018).","journal-title":"J. Clin. Invest."},{"key":"183_CR185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nri.2017.21","volume":"17","author":"AP West","year":"2017","unstructured":"West, A. P. & Shadel, G. S. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat. Rev. Immunol. 17, 363\u2013375 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"183_CR186","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4161\/auto.7.10.16771","volume":"7","author":"LC Gomes","year":"2011","unstructured":"Gomes, L. C. & Scorrano, L. Mitochondrial elongation during autophagy: a stereotypical response to survive in difficult times. Autophagy 7, 1251\u20131253 (2011).","journal-title":"Autophagy"},{"key":"183_CR187","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.21374","volume":"6","author":"S Monterisi","year":"2017","unstructured":"Monterisi, S. et al. PDE2A2 regulates mitochondria morphology and apoptotic cell death via local modulation of cAMP\/PKA signalling. eLife 6, e21374 (2017).","journal-title":"eLife"},{"key":"183_CR188","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2015.39","volume":"11","author":"FT Chebib","year":"2015","unstructured":"Chebib, F. T., Sussman, C. R., Wang, X., Harris, P. C. & Torres, V. E. Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat. Rev. Nephrol. 11, 451\u2013464 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"183_CR189","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","volume":"6","author":"E Meijer","year":"2011","unstructured":"Meijer, E. et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 6, 361\u2013368 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"183_CR190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000013382","volume":"18","author":"G Cerasola","year":"1998","unstructured":"Cerasola, G. et al. Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am. J. Nephrol. 18, 391\u2013398 (1998).","journal-title":"Am. J. Nephrol."},{"key":"183_CR191","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1681\/ASN.V12112427","volume":"12","author":"IH Klein","year":"2001","unstructured":"Klein, I. H., Ligtenberg, G., Oey, P. L., Koomans, H. A. & Blankestijn, P. J. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J. Am. Soc. Nephrol. 12, 2427\u20132433 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"183_CR192","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ncb2220","volume":"13","author":"LC Gomes","year":"2011","unstructured":"Gomes, L. C., Di Benedetto, G. & Scorrano, L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat. Cell Biol. 13, 589\u2013598 (2011).","journal-title":"Nat. Cell Biol."},{"key":"183_CR193","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","volume":"49","author":"JM Banales","year":"2009","unstructured":"Banales, J. M. et al. The cAMP effectors Epac and protein kinase A (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 49, 160\u2013174 (2009).","journal-title":"Hepatology"},{"key":"183_CR194","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","volume":"58","author":"TV Masyuk","year":"2013","unstructured":"Masyuk, T. V. et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58, 409\u2013421 (2013).","journal-title":"Hepatology"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41581-019-0183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-019-0183-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-019-0183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:08:40Z","timestamp":1684606120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-019-0183-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":194,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["183"],"URL":"https:\/\/doi.org\/10.1038\/s41581-019-0183-y","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"17 July 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}